Enveric Biosciences, Inc.
ENVB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $3,141 | $3 | $2,706 |
| - Cash | $3,758 | $2,850 | $4,294 | $2,241 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $291 | -$4,292 | $465 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$40 | -$40 | -$81 | -$82 |
| % Margin | – | – | – | – |
| EBITDA | -$1,833 | -$2,479 | -$2,104 | -$3,065 |
| % Margin | – | – | – | – |
| Net Income | -$1,874 | -$2,519 | -$2,185 | -$3,155 |
| % Margin | – | – | – | – |
| EPS Diluted | -10.81 | -11.64 | -14,584.44 | -57.84 |
| % Growth | 7.1% | 99.9% | -25,115.1% | – |
| Operating Cash Flow | -$2,075 | -$1,890 | -$2,392 | -$1,312 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$2,075 | -$1,890 | -$2,392 | -$1,312 |